NASDAQ:ATRS - Antares Pharma Stock Price, Forecast & News

Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."

Antares Pharma Inc (NASDAQ:ATRS) announced its earnings results on Tuesday, November, 5th. The specialty pharmaceutical company reported $0.01 earnings per share for the quarter, beating analysts' consensus estimates of ($0.02) by $0.03. The specialty pharmaceutical company had revenue of $34.31 million for the quarter, compared to analyst estimates of $26.36 million. Antares Pharma had a negative net margin of 0.56% and a negative return on equity of 1.40%. View Antares Pharma's Earnings History.

Antares Pharma is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Antares Pharma.

Antares Pharma issued an update on its FY 2020 Pre-Market earnings guidance on Monday, January, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $135-155 million, compared to the consensus revenue estimate of $149.16 million.

3 equities research analysts have issued 12 month price objectives for Antares Pharma's shares. Their forecasts range from $1.99 to $5.65. On average, they expect Antares Pharma's share price to reach $4.21 in the next year. This suggests a possible upside of 4.8% from the stock's current price. View Analyst Price Targets for Antares Pharma.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Antares Pharma.

Media coverage about ATRS stock has been trending somewhat negative on Tuesday, according to InfoTrie. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Antares Pharma earned a news impact score of -1.4 on InfoTrie's scale. They also assigned headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Antares Pharma.

Antares Pharma saw a increase in short interest in December. As of December 13th, there was short interest totalling 3,770,000 shares, an increase of 8.6% from the November 28th total of 3,470,000 shares. Based on an average trading volume of 1,630,000 shares, the days-to-cover ratio is currently 2.3 days. Approximately 2.5% of the company's stock are short sold. View Antares Pharma's Current Options Chain.

Some companies that are related to Antares Pharma include Align Technology (ALGN), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), West Pharmaceutical Services (WST), Haemonetics (HAE), ICU Medical (ICUI), Neogen (NEOG), Quidel (QDEL), Merit Medical Systems (MMSI), STAAR Surgical (STAA), Atrion (ATRI), Cerus (CERS), Anika Therapeutics (ANIK), OraSure Technologies (OSUR) and Meridian Bioscience (VIVO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Antares Pharma investors own include Ballard Power Systems (BLDP), Conatus Pharmaceuticals (CNAT), NVIDIA (NVDA), Novavax (NVAX), Prospect Capital (PSEC), Advanced Micro Devices (AMD), Hi-Crush Partners (HCLP), Macquarie Infrastructure (MIC), AT&T (T) and Enviva Partners (EVA).

Antares Pharma's stock is owned by many different of institutional and retail investors. Top institutional investors include California Public Employees Retirement System (0.22%), AE Wealth Management LLC (0.02%) and Optimum Investment Advisors (0.00%). Company insiders that own Antares Pharma stock include Jacques Gonella, Leonard S Jacob, Marvin Samson, Robert F Apple and Thomas J Garrity. View Institutional Ownership Trends for Antares Pharma.

ATRS stock was sold by a variety of institutional investors in the last quarter, including AE Wealth Management LLC. Company insiders that have sold Antares Pharma company stock in the last year include Jacques Gonella, Leonard S Jacob, Marvin Samson, Robert F Apple and Thomas J Garrity. View Insider Buying and Selling for Antares Pharma.

ATRS stock was bought by a variety of institutional investors in the last quarter, including California Public Employees Retirement System and Optimum Investment Advisors. View Insider Buying and Selling for Antares Pharma.

Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ATRS stock can currently be purchased for approximately $4.02.

Antares Pharma has a market capitalization of $656.17 million and generates $63.55 million in revenue each year. The specialty pharmaceutical company earns $-6,510,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis. Antares Pharma employs 165 workers across the globe.View Additional Information About Antares Pharma.

The official website for Antares Pharma is http://www.antarespharma.com/.

Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected]